These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29185714)

  • 1. Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
    Besandre R; Liu HW
    Biochemistry; 2018 Feb; 57(5):479-480. PubMed ID: 29185714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection
    Matthew AN; Kurt Yilmaz N; Schiffer CA
    Biochemistry; 2018 Feb; 57(5):481-482. PubMed ID: 29192768
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Heo YA; Deeks ED
    Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
    N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavyret and Vosevi--two new combinations for chronic HCV infection.
    Med Lett Drugs Ther; 2017 Oct; 59(1531):166-170. PubMed ID: 28977807
    [No Abstract]   [Full Text] [Related]  

  • 8. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
    Mathur P; Kottilil S; Wilson E
    Antivir Ther; 2019; 24(1):1-10. PubMed ID: 30210057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    Karimi-Sari H; Rezaee-Zavareh MS; Falade-Nwulia O; Lim JK
    J Hepatol; 2022 Oct; 77(4):1215-1217. PubMed ID: 35798132
    [No Abstract]   [Full Text] [Related]  

  • 11. New Drugs 2018, part 1.
    Hussar DA
    Nursing; 2018 Feb; 48(2):36-44. PubMed ID: 29324623
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
    Patel S; Martin MT; Flamm SL
    Liver Int; 2021 Dec; 41(12):3024-3027. PubMed ID: 34592051
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
    Ruiz-Boy S; Rodriguez-Reyes M; Sotoca-Momblona JM
    Med Clin (Barc); 2021 Jul; 157(2):85-86. PubMed ID: 32807510
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
    Wong YJ; Kumar R; Kumar R; Tan J; Liu CH; Hui VK; Tan SS; Kao JH; Wong GH; Thurairajah PH
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1642-1644. PubMed ID: 35723645
    [No Abstract]   [Full Text] [Related]  

  • 15. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
    Fawsitt CG; Vickerman P; Cooke G; Welton NJ;
    Value Health; 2019 Jun; 22(6):693-703. PubMed ID: 31198187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
    [No Abstract]   [Full Text] [Related]  

  • 18. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
    Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P
    Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
    Cory TJ; Mu Y; Gong Y; Kodidela S; Kumar S
    Expert Opin Pharmacother; 2018 May; 19(7):749-757. PubMed ID: 29634360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
    Summers BB
    Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.